Viewing Study NCT03016468

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:54 PM
Ignite Modification Date: 2026-02-22 @ 7:02 AM
Study NCT ID: NCT03016468
Status: WITHDRAWN
Last Update Posted: 2017-04-11
First Post: 2017-01-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Sponsor: United Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pulmonary Arterial Hypertension View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Oral Treprostinil View
None Remodulin View
None Selexipag View
None 6 Minute Walk Test View